Skip to main content

A phase?3, randomized, double-blind, Placebo-controlled study to evaluate the efficacy and safety of orally administered deucrictibant extended-release tablet for Prophylaxis against angioedema attacks in adolescents and adults with hereditary angioedema.

Open
  • Protocol code: PHA022121-C305
  • EudraCT code: _
  • Research group: Systemic Diseases
  • Service: Internal Medicine
  • Principal investigator:  Guilarte Clavero, Mar
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase III